<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications</title>
  </titleInfo>
  <name type="personal">
    <namePart>Andrew T Levin</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Nana Owusu-Boaitey</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Sierra Pugh</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Bailey K Fosdick</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Anthony B Zwi</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Anup Malani</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Satej Soman</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Lonni Besançon</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Ilya Kashnitsky</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Sachin Ganesh</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Aloysius McLaughlin</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Gayeong Song</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="">Review articles.</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">xx</placeTerm>
    </place>
    <dateIssued encoding="marc">2022</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <extent>1 online resource (1 article).</extent>
  </physicalDescription>
  <abstract>INTRODUCTION: The infection fatality rate (IFR) of COVID-19 has been carefully measured and analysed in high-income countries, whereas there has been no systematic analysis of age-specific seroprevalence or IFR for developing countries. METHODS: We systematically reviewed the literature to identify all COVID-19 serology studies in developing countries that were conducted using representative samples collected by February 2021. For each of the antibody assays used in these serology studies, we identified data on assay characteristics, including the extent of seroreversion over time. We analysed the serology data using a Bayesian model that incorporates conventional sampling uncertainty as well as uncertainties about assay sensitivity and specificity. We then calculated IFRs using individual case reports or aggregated public health updates, including age-specific estimates whenever feasible. RESULTS: In most locations in developing countries, seroprevalence among older adults was similar to that of younger age cohorts, underscoring the limited capacity that these nations have to protect older age groups.Age-specific IFRs were roughly 2 times higher than in high-income countries. The median value of the population IFR was about 0.5%, similar to that of high-income countries, because disparities in healthcare access were roughly offset by differences in population age structure. CONCLUSION: The burden of COVID-19 is far higher in developing countries than in high-income countries, reflecting a combination of elevated transmission to middle-aged and older adults as well as limited access to adequate healthcare. These results underscore the critical need to ensure medical equity to populations in developing countries through provision of vaccine doses and effective medications.</abstract>
  <note type="statement of responsibility">Andrew T Levin; Nana Owusu-Boaitey; Sierra Pugh [and others].</note>
  <note>The source lists 18 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest.</note>
  <note>Publication type: Review article.</note>
  <note>Linked open-access copy: published version.</note>
  <note>Open access; no subscription required for the linked open-access version. Unrestricted online access star</note>
  <note xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://openalex.org/W4281556556">Creative Commons Attribution-NonCommercial (licence family recorded by the source; version not supplied in metadata). https://openalex.org/W4281556556</note>
  <note>In English.</note>
  <subject>
    <topic>COVID-19 pandemic</topic>
  </subject>
  <subject>
    <topic>infection fatality rate</topic>
  </subject>
  <subject>
    <topic>seroprevalence</topic>
  </subject>
  <subject>
    <topic>developing countries</topic>
  </subject>
  <subject>
    <topic>seroreversion</topic>
  </subject>
  <subject>
    <topic>antibody assays</topic>
  </subject>
  <subject>
    <topic>B. Sc. Political Science</topic>
  </subject>
  <subject>
    <topic>UMUN open access collection</topic>
  </subject>
  <subject>
    <topic>public policy</topic>
  </subject>
  <relatedItem type="host">
    <titleInfo>
      <title>BMJ Global Health</title>
    </titleInfo>
    <identifier type="issn">2059-7908</identifier>
    <part>
      <text>Vol. 7, no. 5, (2022), pages/article e008477</text>
    </part>
  </relatedItem>
  <identifier type="uri">https://gh.bmj.com/content/bmjgh/7/5/e008477.full.pdf</identifier>
  <location>
    <url displayLabel="Read open-access publication">https://gh.bmj.com/content/bmjgh/7/5/e008477.full.pdf</url>
  </location>
  <accessCondition type="restrictionOnAccess">Open access; no subscription required for the linked open-access version.</accessCondition>
  <accessCondition type="useAndReproduction">Creative Commons Attribution-NonCommercial (licence family recorded by the source; version not supplied in metadata).</accessCondition>
  <recordInfo>
    <recordContentSource authority="marcorg">local</recordContentSource>
    <recordCreationDate encoding="marc">261005</recordCreationDate>
    <recordChangeDate encoding="iso8601">20261005174850.0</recordChangeDate>
    <recordIdentifier source="local">UMUN-OA-20261005-PS-023</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
